Market research reports found on the Internet provide estimates
of global sales amounts for active pharmaceutical ingredients (APIs). These estimates suggest that API sales in
2015 were around $150 billion and will be around $ 210 billion in 2020,
assuming the sales compounded annual growth rate from 2015 to 2020 is 6.2%.
Searching the Internet found sixteen companies that report their
API sales separately in annual reports. These companies, along with their most recent
annual reported API sales, are shown in the following table:
|
company
|
country
|
sales 2015 (millions
USD)
|
|
Teva
|
Israel
|
$ 748
|
|
Divis
|
India
|
$ 556
|
|
Cambrex
|
United
States
|
$ 434
|
|
Aurobindo
|
India
|
$ 405
|
|
Dr.
Reddy
|
India
|
$ 381
|
|
Biocon
|
India
|
$ 337
|
|
Siegfried
|
Switzerland
|
$ 333
|
|
Johnson
Matthey
|
United
Kingdom
|
$ 317
|
|
Daito
|
Japan
|
$ 270
|
|
Shandong
Xinhua
|
China
|
$ 226
|
|
Albany
Molecular Research
|
United
States
|
$ 217
|
|
Dishman
|
India
|
$ 165
|
|
Sun
|
India
|
$ 160
|
|
Scinopharm
|
Taiwan
|
$
125
|
|
RPG Life Sciences
|
India
|
$ 41
|
|
Consort
Medical
|
United
Kingdom
|
$ 14
|
|
|
total
|
$ 4,729
|
As shown in the table, the total API sales reported by these
companies are $4.729 billion. This represents
a very small percentage (3%) of the total estimated API sales ($150 billion) provided
by market research reports ($4.729 billion/$150 billion = 3%).
One question with such a small percentage (3%) is how reliable
is the $150 billion amount for total global 2015 API sales provided by market research
companies. Also interesting from the table's
data is the extent of India’s API sales.
Seven of the sixteen companies listed in the table are Indian with their
API sales representing 43% ($2.045 billion/4.729 billion) of the total sales.
No comments:
Post a Comment